Company intelligence / Profile preview

Lavie Bio

Rehovot, Central District, Israellavie-bio.com ↗

Ownership: Public · ICL
Employees: ~50
Development stage: Commercial

Overview

Lavie Bio develops microbiome-based agricultural biological products—bio-stimulants and bio-pesticides—to improve crop yield, sustainability, pest management, and food quality. Its proprietary computational platform leverages big data/AI for rapid discovery. The company has advanced several programs toward commercialization with ongoing industry partnerships. In April 2025 ICL agreed to acquire most of its assets/programs from parent Evogene.

Therapeutic areas: OtherInfectious Diseases
Modalities: Live biotherapeutic product therapyMicrobial therapyBiologic
Industry: Agriculture & AgTech

Drug pipeline

4 assets

LAV228

Pre-development

Indications: Soybean treatment

3 more assets in the full pipeline.

Request access →

Partnerships

Corteva AgriscienceICL Group

Beyond the preview

Go deeper on Lavie Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lavie Bio.

Explore the full profile